GENB vs IQV
GENB: Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein therapeutics. IQV: IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2 billion de-identified patient records.
Side-by-side fundamentals
| Metric | GENB | IQV | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.90 | $198.52 | |
| Market cap as of 2026-07-23 | $1.8B | $33.2B | |
| P/E as of 2026-07-23 | n/a | 23.98 | |
| PEG as of 2026-07-23 | n/a | 2.51 | |
| Net margin as of 2026-07-23 | -637.0% | +8.3% | IQV higher |
| Gross margin as of 2026-07-23 | n/a | +33.0% | |
| Operating margin as of 2026-07-23 | -737.0% | +13.2% | IQV higher |
| ROE as of 2026-07-23 | -103.7% | +22.5% | IQV higher |
| ROA as of 2026-07-23 | -61.5% | +4.7% | IQV higher |
| Debt / equity as of 2026-07-23 | 0.01 | 2.55 | GENB lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +7.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.52 | 1.20 | |
| 1-year return as of 2026-07-22 close | +13.8% | +26.8% | IQV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.